You are viewing: Europe Biobanking Market analysis
Part of: Biobanking Market (Global)

The Europe Biobanking Market was valued at $1977.3 Million in 2025 and projected to reach to $3037.4 Million by 2030, representing a compound annual growth rate of 9.0%. Europe's biobanking market is poised for sustained expansion through 2030, driven by increasing demand for personalized medicine, growing genomic research initiatives, and robust healthcare infrastructure investments.

Europe Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Biobanking Market Trends and Insights

  • This 9.0% compound annual growth rate reflects Europe's strong regulatory framework, advanced healthcare infrastructure, and increasing investment in precision medicine and genomic research.
  • Europe leads in standardized biobanking protocols and cross-border sample sharing initiatives, positioning the region as a critical hub for biomedical innovation. The European biobanking sector is driven by rising demand for personalized medicine, growing prevalence of chronic diseases, and substantial public and private funding for life sciences research.
  • Europe's commitment to data protection through GDPR and harmonized ethical standards enhances trust in biobanking operations across member states.
  • By 2030, Europe is expected to maintain its competitive advantage through continued technological advancement and collaborative research networks that leverage biobanked samples for drug discovery and clinical trials..

Key Market Statistics

  • CAGR (2025-2030) 9.0% CAGR
  • Market Size, 2025 ~USD 1977.3 Million
  • Forecast, 2030 ~USD 3037.4 Million
  • Geography Europe

Europe Biobanking Market Overview

Market Valuation & Growth :

Europe's biobanking market is valued at $1,977.3 million in 2025 and is projected to reach $3,037.4 million by 2030, representing a steady 9.0% CAGR. This growth trajectory demonstrates strong investor confidence and increasing adoption across the region.

Regulatory Leadership :

Europe maintains the world's most stringent and standardized biobanking protocols, driven by GDPR compliance, tissue directives, and ethical frameworks. This regulatory excellence positions European biobanks as gold standards for data integrity and patient privacy protection.

Precision Medicine Investment :

Significant European investment in precision medicine and genomic research initiatives is accelerating biobank expansion. National genomic programs and EU-funded research consortia are driving demand for high-quality biological samples and associated data infrastructure.

Cross-Border Collaboration :

Europe's advanced healthcare infrastructure enables seamless cross-border biobank networks and sample sharing. Initiatives like the European Biobanking and BioMolecular Resources Research Infrastructure (BBMRI-ERIC) facilitate international research collaboration and standardization.

Europe Biobanking Market Dynamics

  • The region's commitment to data standardization and regulatory compliance creates competitive advantages for biobanking service providers and attracts global research partnerships. Key growth catalysts include expanding precision oncology programs, rising prevalence of chronic diseases requiring biomarker research, and increased pharmaceutical R&D spending across the continent.
  • European biobanks are increasingly leveraging artificial intelligence and digital pathology to enhance sample management and research capabilities, positioning the region as a leader in next-generation biobanking solutions..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Europe's biobanking market will grow from $1,977.3M (2025) to $3,037.4M (2030) at a 9.0% CAGR, driven by precision medicine adoption and genomic research investment.
    • Europe's regulatory leadership through GDPR and harmonized ethical standards creates competitive advantages in cross-border biobanking and sample sharing.
    • Rising chronic disease prevalence and substantial public-private funding fuel demand for biobanked samples in drug discovery and clinical trial applications across Europe.
    • Europe's collaborative research networks and standardized biobanking protocols position the region as a global leader in biomedical innovation through 2030.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Europe Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    REST OF EUROPE: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES25.225.727.73032.735.739.142.89.1
    HOSPITALS & DIAGNOSTIC LABORATORIES15.515.816.918.319.821.523.525.68.7
    PHARMA-BIOTECH COMPANIES & CROS59.460.965.771.578.185.693.9103.39.5
    TOTAL100.1102.5110.3119.8130.6142.8156.4171.79.3

    EUROPE: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS923.3945.11002.31074.81159.61256.51366.91492.98.3
    CROS270274.6289.4308.3330.5355.9384.6417.47.6
    TOTAL1193.31219.71291.71383.21490.11612.41751.61910.38.1

    Target Audience

    • Pharmaceutical & Biotech Companies : European market data enables drug developers to identify biobank partnerships, access quality biological samples, and accelerate clinical research programs aligned with precision medicine initiatives across the continent.
    • Healthcare Providers & Hospital Networks : Hospital systems and healthcare networks require insights into biobanking infrastructure investments, patient sample management solutions, and regulatory compliance strategies to enhance research capabilities and patient care.
    • Research Institutions & Universities : Academic and research organizations need market intelligence on funding opportunities, collaborative networks, and biobanking best practices to strengthen genomic research programs and secure competitive research grants.
    • Biobanking Service Providers : Biobank operators and sample management companies require detailed market analysis to identify expansion opportunities, benchmark service offerings, and develop competitive strategies in Europe's growing biobanking market.
    • Healthcare Investors & Private Equity : Investment firms evaluating biobanking sector opportunities need comprehensive market data, growth forecasts, and regional insights to make informed investment decisions and identify high-potential acquisition targets.

    Key Companies in the Europe Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 5156.4 Million · 9.2% wtd CAGR ·
    Asia Pacific
    ~USD 2567.8 Million · 9.6% wtd CAGR ·
    Latin America
    ~USD 555.4 Million · 8.6% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 850.8 Million
    UKUSD 617.2 Million
    FranceUSD 298.6 Million
    ItalyUSD 192.6 Million
    SpainUSD 137.9 Million
    Rest Of EuropeUSD 357 Million

    Country market size visualization

    Germany
    USD 850.8 Million
    UK
    USD 617.2 Million
    France
    USD 298.6 Million
    Italy
    USD 192.6 Million
    Spain
    USD 137.9 Million
    Rest Of Europe
    USD 357 Million

    Reasons to Buy this Report

    • Country-Level Market Insights : Detailed market sizing for Germany ($850.8M), UK ($617.2M), France ($298.6M), Italy ($192.6M), and Spain ($137.9M) enables targeted market entry strategies and competitive positioning across Europe's largest biobanking markets.
    • Regulatory & Compliance Framework : Comprehensive analysis of Europe's stringent GDPR, tissue directives, and ethical standards helps organizations navigate complex regulatory landscapes and build compliant biobanking operations that meet international quality benchmarks.
    • Growth Opportunity Identification : Strategic insights into precision medicine adoption, genomic research funding, and cross-border collaboration networks reveal high-growth segments and partnership opportunities across the European biobanking ecosystem.
    • Competitive Landscape Analysis : In-depth understanding of European biobanking leaders, emerging players, and service providers enables informed investment decisions and strategic partnerships to capture market share in this rapidly expanding sector.
    • 2030 Forecast Planning : Detailed projections through 2030 support long-term strategic planning, capital allocation, and resource optimization for organizations seeking to establish or expand biobanking operations across Europe.

    Frequently asked questions

    What is the current size of Europe's biobanking market in 2025?

    Europe's biobanking market is valued at $1,977.3 million in 2025, reflecting strong demand for sample storage and genomic research infrastructure across the region.

    What is the projected size of Europe's biobanking market by 2030?

    Europe's biobanking market is forecast to reach $3,037.4 million by 2030, representing a 9.0% compound annual growth rate over the five-year period.

    What are the main drivers of growth in Europe's biobanking market?

    Key growth drivers in Europe include rising adoption of precision medicine, increasing prevalence of chronic diseases, substantial public and private research funding, and strong regulatory frameworks supporting ethical biobanking practices.

    How does Europe's regulatory environment support biobanking growth?

    Europe's GDPR compliance, harmonized ethical standards, and cross-border data protection regulations create a trustworthy environment that facilitates collaborative biobanking initiatives and international sample sharing.

    Which applications are driving demand for biobanked samples in Europe?

    Primary applications include drug discovery, clinical trials, personalized medicine development, and genomic research, all supported by Europe's advanced healthcare infrastructure and research institutions.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status